Calciphylaxis Treatment Global Market Report 2024

The calciphylaxis treatment market size has grown rapidly in recent years. It will grow from $1.68 billion in 2023 to $1.86 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth observed in the historical period can be attributed to the increasing incidence of calciphylaxis, a heightened awareness among healthcare professionals, the expansion of healthcare infrastructure, and advancements in clinical research and drug development.

The calciphylaxis treatment market size is expected to see strong growth in the next few years. It will grow to $2.62 billion in 2028 at a compound annual growth rate (CAGR) of 9.1%. The anticipated growth in the forecast period can be attributed to the rise in healthcare expenditure, increasing collaboration and partnerships within the healthcare industry, a focus on personalized medicine, regulatory support, expedited approvals, and the adoption of patient-centric healthcare approaches. Major trends expected in the forecast period include the emergence of new therapeutic modalities, advancements in diagnostics, increased emphasis on research and development, collaborative initiatives within the healthcare sector, and a dynamic regulatory landscape that influences the industry.

The anticipated rise in the prevalence of kidney diseases is set to drive the growth of the calciphylaxis treatment market. Kidney diseases, affecting the vital function of filtering waste products and excess fluids, disrupt calcium and phosphate metabolism, increasing the risk of calciphylaxis. With an estimated 7.19 million people affected by chronic kidney disease in the UK in 2023, representing over 10% of the population and expected to reach 7.61 million by 2033, the growing prevalence of kidney diseases will be a key driver for the calciphylaxis treatment market.

The expansion of ongoing clinical trials is expected to further boost the calciphylaxis treatment market. Clinical trials play a pivotal role in assessing the safety and efficacy of potential treatments, contributing valuable evidence for improved therapeutic approaches. With the number of registered studies increasing from 437,523 in 2022 to 468,457 in 2023 globally, the ongoing clinical trials provide essential insights and advancements in the medical understanding and treatment of calciphylaxis, contributing to the market's growth.

The lack of specific treatment options for calciphylaxis is anticipated to impede the market's growth. Calciphylaxis treatment faces challenges due to the rarity and severity of the vascular disorder, characterized by tissue necrosis from small vessel calcification. Limited therapeutic options for this serious condition pose significant medical challenges, with a low chance of recovery and no approved therapy for calciphylaxis, creating a hindrance in effectively addressing the disorder.

Leading companies in the calciphylaxis treatment market are focusing on developing advanced diagnostic techniques and health evaluation services to enhance profitability. By introducing comprehensive in-home kidney health evaluations, companies such as Signify Health, Inc. aim to provide convenient and proactive monitoring solutions for kidney health. Such initiatives, including urinalysis and estimated glomerular filtration rate assessments, prove valuable in early detection and management of chronic kidney health issues, including conditions such as calciphylaxis.

In November 2021, Vifor Pharma Group acquired Sanifit Therapeutics S.A. for $409 million (€380 million). This acquisition enhances Vifor Pharma Group's position in the nephrology market, leveraging Sanifit's lead compound, SNF472, to address vascular calcification. With a focus on providing therapeutic benefits to calciphylaxis patients and strengthening its nephrology portfolio, the acquisition positions Vifor Pharma Group as a key player in the calciphylaxis treatment market.

Major companies operating in the calciphylaxis treatment market report are Pfizer Inc., Merck And Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi SA, 3M Company, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Novo Nordisk, Viatris (Mylan N.V.), Regeneron Pharmaceuticals Inc., Smith And Nephew Plc., Incyte Corporation, ConvaTec Inc., Vifor Pharma Group, BSN Medical GmbH, Panion And BF Biotech Inc., Inozyme Pharma Inc., Sanifit Therapeutics S.A, Hope Pharmaceuticals, Menlo Therapeutics.

North America was the largest region in the calciphylaxis treatment market in 2023 Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calciphylaxis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the calciphylaxis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Calciphylaxis, also known as calcific uremic arteriolopathy (CUA), is a rare and severe medical condition characterized by the deposition of calcium in small blood vessels and tissues. It primarily affects individuals with kidney disease, especially those with end-stage renal disease (ESRD). The treatment approach involves pain management and nutritional support therapies to address symptoms such as painful and non-healing skin ulcers, tissue necrosis, and potential complications such as sepsis, which can pose life-threatening risks.

The main types of calciphylaxis treatment include medication, hyperbaric oxygen therapy, and other interventions. Medication involves the use of pharmaceutical drugs to manage symptoms and underlying causes. Medications such as sodium thiosulfate, opioids, or non-opioid drugs may be employed to treat or prevent infections, manage pain, and address aspects associated with calciphylaxis. Diagnosis is typically carried out through imaging, blood tests, and deep skin biopsies performed by end users such as hospitals, clinics, medical research centers, and academic institutes.

The calciphylaxis treatment market research report is one of a series of new reports that provides calciphylaxis treatment market statistics, including calciphylaxis treatment industry global market size, regional shares, competitors with an calciphylaxis treatment market share, detailed calciphylaxis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the calciphylaxis treatment industry. This calciphylaxis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The calciphylaxis treatment market consists of revenues earned by entities by providing diagnostic services such as infrared thermography, electrolyte and mineral analysis, and measuring serum parathyroid hormone (PTH) levels to diagnose and assess the severity of calciphylaxis in patients. The market value includes the value of related goods sold by the service provider or included within the service offering. The calciphylaxis treatment market also includes sales of intensive wound care, clot-dissolving therapy, and vitamin K therapy, which are comprehensive treatment approaches for managing calciphylaxis. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.